Performance & how we report

By investing in energy optimisation and shifting to renewable energy we have cut carbon emissions from our global production sites by almost 60% since 2004.

We use energy in all parts of our production - from fermentation through filling of our product. In 2018, energy consumption remained stable compared to 2017. We continue to focus on energy efficiency, and projects implemented in 2018 are expected to give annual savings of more than 53,000 GJ - more than tripling the savings in 2017.

The overall CO2 emissions from energy consumption in production in 2018, decreased by 2% compared to 2017, due to decreased energy use in areas that use fossil-based energy.


Zero Emissions from Operations and Transportation

In 2018, Novo Nordisk committed to a new long-term strategy, Circular for Zero, aiming to achieve zero emissions from operations and transportation. This includes all CO2 emissions from production, global offices and laboratories, product distribution, business flights and company cars. The total CO2 emissions in 2018 were 269,000 tons CO2.

As a part of the new long-term environmental target, Novo Nordisk will have zero emissions from transportation by 2030. Therefore, reducing emissions from company cars, business flights and product distribution is a priority.

Novo Nordisk distributes as many products as possible by sea, as it reduces CO2 emissions and costs. To reduce business travel, we encourage the use of virtual meeting platforms like Skype for Business, video conferencing (VCON) and telepresence.


Graph - CO2 emissions from operations and transport

Furthermore, in 2017 we adopted guidelines for company cars which will lead to increased use of electric and hybrid cars across the company. In Denmark, a small fleet of leased electric cars has reduced the use of taxis for transportation between our sites, and bicycles are available for short distances.

To encourage commuting by public transport, we offer employees in Denmark participation in a scheme that gives a tax deduction of up to 50% of their total transportation cost.

Going 100% renewable power

In 2015, we joined RE100. RE100 is a collaborative, global initiative of businesses, which are committed to using 100% renewable power and are working to increase demand for - and delivery of - renewable energy.

At the end of 2018, 77% of all electricity was from renewable sources. All production sites in Denmark use electricity from wind, our production in China sources renewable energy from wind, and the facility in Brazil uses hydropower.

Novo Nordisk is well on track to reach its RE100 goal of achieving 100% renewable power for production by 2020. A long-term solution for renewable power in Europe was finalised in 2018 with the power company, Vattenfall. This solution will secure power from Danish windfarms to Novo Nordisk’s European production sites from 2020. During 2018, Novo Nordisk continued to explore opportunities with energy suppliers in the US for renewable power solutions for all Novo Nordisk's activities in the US.


Share of electricity from renewable sources

  • In 2016, the share of electricity from renewable sources was 78%
  • In 2017, the share of electricity from renewable sources was 79%
  • In 2018, the share of electricity from renewable sources was 77%.

How we report

In 2018, we were awarded the performance score ‘A’ on the CDP Climate A list. This is the 16th time we report to CDP.1

More detailed CDP scores

More information can be found in the Novo Nordisk Annual Report 2018.


1. We report CO2 according to the GHG protocol. We use various sources and methodologies to calculate CO2 emissions. Carbon emissions from use of energy are based on GJ energy use and emission factors from the previous year. The calculation of emissions from our supply of services and goods is based on the EP&L methodology (spend data) and updated on an annual basis. Calculation of emissions from our use of raw materials is based on tons of materials used and Lifecycle Assessment (LCA) data, and updated every second year.